Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
itching
Biotech
Connect uncouples from Pfizer by scrapping eczema pact
Connect licensed the oral, peripherally acting H3R antagonist in 2012 from Arena, a company that Pfizer bought for $6.7 billion a decade later.
Nick Paul Taylor
Apr 17, 2024 6:38am
Itch treater Cara cuts 50% of team to extend runway into 2026
Jan 22, 2024 9:44am
Breaking the vicious itch-scratch cycle via 'miswired' neurons
Jul 14, 2022 5:08am
Evommune snags $83M for "Tylenol for itch," three other programs
Sep 9, 2021 7:30am
Cara's stock tanks as atopic dermatitis phase 2 misses endpoint
Apr 30, 2021 8:25am
J&J's allergy-fighting contact lens nets first approval in Japan
Mar 24, 2021 10:18am
